1093819-33-0

Basic information

• Product Name: N-(5-bromopyridin-3-yl)propane-2-sulfonamide
• Synonyms: N-(5-bromopyridin-3-yl)propane-2-sulfonamide
• CAS NO: 1093819-33-0
• Molecular Formula: C8H11BrN2O2S
• Molecular Weight: 279.15414
• Mol File: 1093819-33-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-(5-bromopyridin-3-yl)propane-2-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-bromopyridin-3-yl)propane-2-sulfonamide(1093819-33-0)
• EPA Substance Registry System: N-(5-bromopyridin-3-yl)propane-2-sulfonamide(1093819-33-0)

Safety Data

• Hazardous Substances Data: 1093819-33-0(Hazardous Substances Data)

Usage

General Description

N-(5-bromopyridin-3-yl)propane-2-sulfonamide is a chemical compound with a molecular formula C8H10BrN2O2S. It is a sulfonamide derivative with a bromopyridine group attached to a propane chain. N-(5-bromopyridin-3-yl)propane-2-sulfonamide has potential biological and medicinal properties, and it may be used in the development of pharmaceutical products. Its exact applications and properties would depend on the specific research and studies conducted on this compound, but its unique structure suggests potential for various chemical and biological interactions.

Upstream product

• 13535-01-8 3-amino-5-bromopyridine 
• 10147-37-2 Isopropylsulfonyl chloride 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of P13 kinases using quinazoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinazoline derivatives.